EORTC - European Organisation for Research and Treatment of Cancer’s Post

Fortrea's expert panel will explore the current and future landscape of these CAR-T therapy, highlighting its diverse applications and potential. From revolutionizing treatment approaches in non-oncological diseases to leveraging operational oncology experience for broader therapeutic insights, this webinar will provide valuable lessons and insights into the transformative power CAR-T therapy across various therapeutics.

Excellent panel here.

I want to thank patients, investigators and their staff for participating in our clinical trial with monotherapy #roginolisib, which was presented by #AnnaMariaDiGiacomo at this year´s Annual Meeting of the American Society of Clinical Oncology (#ASCO2024) in Chicago (see https://lnkd.in/dFpfc_cX; also see: ASCO® 2024 Insights: "Roginolisib, an Oral, Highly Selective and Allosteric Modulator of PI3Kd for Uveal Melanoma and Advanced Cancers" | VuMedi).  We are excited to learn more about the activity of roginolisib in patients with metastatic uveal melanoma as we continue to analyze the biomarker data from patients treated with #roginolisib. Such data will be presented at future medical conferences.

Exciting News from Carevive: Elevating Patient Experience in Oncology Research! Our Real-World Evidence (RWE) team, alongside our esteemed partners, recently showcased groundbreaking posters at prestigious conferences including ISPOR, ASCO, ASCO Quality, and ASH. These presentations, the culmination of collaborative efforts with leading academic institutions, underscore our commitment to advancing oncology research. We're proud to announce a significant milestone: the publication of three posters in collaboration with Takeda, shedding light on the patient experience in various hematologic malignancies. These publications mark our inaugural joint endeavors with industry, reinforcing our dedication to impactful partnerships. At Carevive, our mission to spearhead patient experience data in oncology remains unwavering. As we continue to build our 2024 collection, we invite you to explore our 2023 repository of publications and posters. https://lnkd.in/eceMxc3x Aaron Galaznik Keri Collette Mordecai Kramer Emelly Rusli Bruno Lempernesse Nadia Still DNP, RN April Boyd #carevive #digitaloncology #cancer #cancercare #oncology #patientreportedoutcomes #oncologydata  #clinicalinnovation #drugcommercialization #RWD #RWE #smartdata

In our recent Peer Exchange episodes, leading pharmacists Ryan Haumschild PharmD, MS, MBA, CPEL; Frank Scimeca, PharmD, MBA, BCOP; Heather Moore, PharmD, BCOP, CPP; and Britny Brown, PharmD, BCOP, present the latest and highly relevant data on CDK4/6 inhibitors in metastatic breast cancer. Join the panel of oncology treatment experts to learn about the significance of adherence, overall survival impact, and effective management strategies. Expand your understanding of early breast cancer with valuable insights. Start watching here: https://bit.ly/4by3nXj.

A new paper on equitable trial methodologies has been published in JAMA Oncology - VCCC Alliance https://lnkd.in/geYGKDV9 #oncodaily #oncology #cancer #research #JAMAOncology

Read the experts summary of recommendations on implementing #precision #oncology program #cancer #cancercare #cancerresearch #precisionmedicine

In an IN VIVO article by Melanie Senior, our CEO Patrick Roberts discussed the ongoing Phase 1/2 trial evaluating our novel, potent and selective #CDK2 inhibitor in ER+/HER2- breast cancer and CCNE1-amplified cancers, and the potential of CDK inhibitors to reshape the #cancer treatment paradigm. Read the full article here: https://lnkd.in/eXb54fiJ (subscription required)

Oncology accounts for 43% of current and planned clinical trials. Cancer is not even a top 10 global cause of death, according to the WHO. Only in mid/high-income countries did a form of cancer (Lung, Colon) represent a top-10 cause of death. Out of the 33,594 ongoing or upcoming phase I-III clinical trials with publicly available data, Oncology trials make up nearly 43%. https://lnkd.in/dnis9xWt

Sometimes its the simple things that can make a difference in patient experience. We are so excited that we have the ability to give subcutaneous trastuzumab (Herceptin)/pertuzumab (Perjeta) instead of IV in our #Nashville practice SCRI Oncology Partners. Article out today in JCO Oncology Practice about the impacts of sub-q administration vs. IV administration of these #HER2 agents. Spoiler alert ⚠: SQ trastuzumab/pertuzumab translated to over 1 hour less ⏰ chair time for patients at EACH administration. Subcutaneous vs Intravenous Trastuzumab/Pertuzumab: A Time and Motion Substudy of a Phase II Trial of Adjuvant Trastuzumab/Pertuzumab for Stage I HER2+ Breast Cancer (ADEPT trial) | JCO Oncology Practice (ascopubs.org)